Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked in the top 5,000 websites in the United States by Alexa.com/Amazon.com, has created one of the finest chat programs available for investors. Now you can chat real-time with like-minded individuals about your favorite stock. Visit Stockwire.com and click the “Chat Live” button at the top.
----------------------------------------------------------
Chat real-time with other investors about this CHVC news release, by
clicking this link: http://www.stockwire.com/CHVC
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=CHVC
China Voice holding Corp (PinkSheet: CHVC)
Asian Stock Review Issues Research Update for China Voice Holding Corporation
OAK PARK, Ill., Oct 26, 2007 Asian Stock Rev has issued a Report Update today on China Voice Holding Corp.
China Voice Holding Corp. is a U.S. public holding company headquartered in South Florida with a portfolio of next-generation communications products and services doing business in the People's Republic of China and the U.S. Through its subsidiaries, the Company provides Voice over Internet Protocol ("VoIP") telephone services, office automation, wireless broadband, unified messaging, video conferencing, mobility services and other advanced voice and data services in China where the Company has obtained full legal status as a licensed telecommunications company. The Chinese telecommunications market is the largest and fastest growing in the world, with 812 million fixed land line and mobile phone subscribers as of September of 2006. As of December 2006, China had 137 million Internet users, an increase of 23% over 2005. China is expected to overtake the United States as the country with the largest number of Internet users in approximately two years. CHVC's focus is on providing its innovative and patented voice and data solutions to government agencies and large enterprises in China.
----------------------------------------------------------
Chat real-time with other investors about this IDMI news release, by
clicking this link: http://www.stockwire.com/IDMI
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=IDMI
Idm Pharma Inc (NASDAQ GM: IDMI)
IDM Pharma Announces Upcoming Clinical Data Presentations
IRVINE, Calif., Oct 26, 2007 IDM Pharma, Inc. a biotechnology company focused on the development of innovative cancer therapies, today announced details on clinical data presentations evaluating three of the Company's pipeline compounds to be presented at upcoming medical congresses.
Oral presentation -- Thursday, November 1, 1:30 p.m. PDT
"Osteosarcoma: Improved Outcome of Muramyl Tripeptide (MTP) to Cisplatin, Doxorubicin, High Dose Methotrexate +/- Ifosfamide." Dr. Paul Meyers, principal investigator, vice chairman, department of pediatrics at Memorial Sloan Kettering Cancer Center Abstract #780 The 39th Congress of International Society of Pediatric Oncology (SIOP) -- Mumbai, India Poster presentation -- Friday, November 2, 4:30 -- 6 a.m. EDT "Lung and Bone Specific Site-Directed Therapy of Osteosarcoma" Dr. Johannes Wolff, professor of pediatrics, The University of Texas M.D. Anderson Cancer Center in Houston Dr. Maurizio Ghisoli, fellow, pediatric oncology and hematology, The University of Texas M.D. Anderson Cancer Center in Houston Poster #PD.037 IDM-2101: International Society for Biological Therapy of Cancer (iSBTc) -- Boston, Mass.
Oral presentation (Vaccines/Dendritic Cells) -- Sunday, November 4, 8:45 - - 11 a.m. EST "Phase 2 Trial of a 10-epitope CTL Vaccine, IDM-2101, in Metastatic NSCLC Patients: Induction of Immune Responses and Clinical Efficacy" Dr. Minal Barve, practice director, Mary Crowley Medical Research Center UVIDEM(R): International Society for Biological Therapy of Cancer (iSBTc) -- Boston, Mass.
Poster presentation -- Friday, November 2, 10 a.m. -- 6 p.m. EDT Saturday, November 3, 7 a.m. -- 6:30 p.m. EDT "Clinical Efficacy and Immunogenicity of IDD-3/UVIDEM, a Dendritic Cell-based Vaccine, in Patients with Malignant Melanoma." Poster #112 About IDM Pharma IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.
----------------------------------------------------------
Chat real-time with other investors about this ONCO news release, by
clicking this link: http://www.stockwire.com/ONCO
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=ONCO
Oncology Med Inc Del (Pink sheets: ONCO)
Oncology Med's New Contracts Reported in the Pittsburgh Business Times on Friday, October 19, 2007 New Contracts Value Could Reach $1,000,000 Over a Two-Year Period
PITTSBURGH, PA, Oct 25, 2007 Oncology Med, Inc. (PINKSHEETS: ONCO), a Pittsburgh-based cancer treatment solutions group, announced today that an article appeared in the Pittsburgh Business Times about its new contract and company operations. The article as summarized on their website appears below: Friday, October 19, 2007 Green Tree firm wins contract to support Ohio health system Value of deal over five years could reach $1M A Green Tree company will soon provide radiation support services for part of the biggest health system in Ohio.
Oncology Med Inc. is set to provide brachytherapy technical support, equipment, radioactive materials and other services at three hospital outpatient clinics run by Youngstown-based Humility of Mary Health Partners: St. Elizabeth Health Center, St. Elizabeth Boardman Health Center and St. Joseph Health Center.
Humility of Mary is part of Catholic Healthcare Partners, a system that includes 29 hospitals as well as long-term-care facilities, home health agencies and other programs.
The two-year contract has a renewal option for three more years, and the value could reach $1 million, said Oncology Med President and Chairman William Walker. The contract became effective Oct. 2.
About Oncology Med, Inc.
Oncology Med is a public company engaged in the fulfillment of services related to the treatment of various cancers. It currently provides analysis and design of radiation treatment plans in order for radiation oncologists to administer radiation treatments to cancer patients. Current services facilitate radiation treatment programs ranging from external beam radiation to more advanced radiation treatment technologies.
More information about Oncology Med, Inc. can be found at www.oncologymed.com.
----------------------------------------------------------
As a trader, a very intelligent place to put your money, is where the money is flowing into. These are the kind of trades that you want to get into.
As the saying goes...follow the money!
To see the complete Movers & Shakers Blog go to: http://www.stockwire.com .
About Stockwire:
Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE RESEARCH GROUP INC..
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the National Association of Securities Dealers ("NASD") at www.nasd.com. The NASD has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com, which is owned by Stockwire Research Group Inc. (SRGI). To the degrees enumerated herein, this newsletter and website should not be regarded as an independent publication.
All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company on Stockwire.com is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.
We often accept restricted shares of company stock; by SEC regulations, restricted shares cannot be sold into the market for a period of at least one year from the time that the shares are issued. In such cases, we detail in the Disclaimer the specific term of any restrictions. We also receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. In such circumstances, we specify on our Disclaimer the terms of the options received. On occasion, we also accept free-trading shares in a company that we cover. We intend to sell these shares at any given time.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .
The Stockwire Group .
512.358.8440 .
info@stockwire.com .
